No Data
Hong Kong stocks unusual movement | Ascentage Pharma-B (06855) up nearly 3%, surpassing the Krysa NDA CED acceptance by force, institutions point to the difficulty of becoming the first domestic drug target.
As of the time of writing, AstraZeneca Pharmaceuticals-B (06855) rose nearly 3%, with an increase of 2.67% to 42.25 Hong Kong dollars, and a turnover of 49.0676 million Hong Kong dollars.
Guosheng Securities: The trend of the domestic innovative drug industry is gradually shifting from license-in to license-out.
Against the backdrop of fierce competition and internal circulation of innovative drug targets in the domestic market, going global is expected to break through the profit ceiling of the domestic market and follow the trend of global innovation.
In half a year, the stock price has doubled, and the commercialization of Asia Sheng Pharmaceutical-B (06855) APG-2575 is imminent, with an expected increase in valuation.
On November 17th, Yasheng health care a announced that the New Drug Application (NDA) for the core variety Bcl-2 inhibitor APG-2575 (proposed Chinese common name: Lisheng Piao) in the company's apoptosis pipeline has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and recommended for priority review, for the treatment of refractory or relapsed (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This undoubtedly marks a key milestone for Yasheng health care a's APG-2575, heralding the official countdown to commercialization of the product.
Express News | Ascentage Pharma Says China's Nmpa Accepts New Drug Application for Co's Novel Bcl-2 Inhibitor Lisaftoclax
Ascentage Pharma Group International's (HKG:6855) Market Cap Dropped HK$1.1b Last Week; Retail Investors Bore the Brunt
Three clinical studies of Ascentage Pharma's Bcl-2 inhibitor APG-2575 were selected for presentation at the 2024 ASH conference, including one oral presentation!
Rockville City, Maryland, usa and Suzhou, china, November 6, 2024 / PRNewswire / - Ascentage Pharma (6855.HK), a leading biomedical company dedicated to developing innovative drugs in fields such as oncology, announced today that its key product APG-2575 (Lisaftoclax) has a total of 3 clinical advancements selected for the 66th American Society of Hematology (ASH) annual meeting, including one oral presentation. This marks the third consecutive year that this product's clinical advancements have been selected for the ASH annual meeting.
No Data
No Data
